MX2021013980A - Compuesto para el tratamiento de gota o hiperuricemia. - Google Patents

Compuesto para el tratamiento de gota o hiperuricemia.

Info

Publication number
MX2021013980A
MX2021013980A MX2021013980A MX2021013980A MX2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A
Authority
MX
Mexico
Prior art keywords
hyperuricemia
compound
treating gout
treating
gout
Prior art date
Application number
MX2021013980A
Other languages
English (en)
Inventor
Shunqi Yan
Litain Yeh
Rongzi Yan
Zancong Shen
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of MX2021013980A publication Critical patent/MX2021013980A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

En el presente documento se describe (3,5-dibromo-4-hidroxifenil) (6-hidroxi-2-(1-hidroxietil)benzofuran-3-il-4,5,7-d3)metanona, o una sal o solvato farmacéuticamente aceptable de la misma, y métodos para tratar o prevenir la gota o la hiperuricemia que comprenden la administración del compuesto.
MX2021013980A 2019-05-14 2020-05-13 Compuesto para el tratamiento de gota o hiperuricemia. MX2021013980A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (1)

Publication Number Publication Date
MX2021013980A true MX2021013980A (es) 2022-04-01

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013980A MX2021013980A (es) 2019-05-14 2020-05-13 Compuesto para el tratamiento de gota o hiperuricemia.

Country Status (14)

Country Link
US (1) US20220242841A1 (es)
EP (1) EP3968989A4 (es)
JP (1) JP2022533958A (es)
KR (1) KR20220016105A (es)
CN (1) CN113874014A (es)
AU (1) AU2020274165A1 (es)
BR (1) BR112021022843A2 (es)
CA (1) CA3140412A1 (es)
IL (1) IL288034A (es)
MA (1) MA55973A (es)
MX (1) MX2021013980A (es)
SG (1) SG11202112562XA (es)
TW (1) TW202108561A (es)
WO (1) WO2020232156A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214228A (zh) * 2020-06-10 2022-04-16 美商安索治療公司 治療或預防慢性腎臟病之方法
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
TW202334103A (zh) * 2021-12-30 2023-09-01 美商安索治療公司 用於治療痛風或高尿酸血症之化合物之製備

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
CA3030821A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
US20210130312A1 (en) * 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
JP2022511800A (ja) * 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Also Published As

Publication number Publication date
WO2020232156A1 (en) 2020-11-19
MA55973A (fr) 2022-03-23
CA3140412A1 (en) 2020-11-19
CN113874014A (zh) 2021-12-31
KR20220016105A (ko) 2022-02-08
IL288034A (en) 2022-01-01
EP3968989A1 (en) 2022-03-23
JP2022533958A (ja) 2022-07-27
BR112021022843A2 (pt) 2022-03-03
TW202108561A (zh) 2021-03-01
EP3968989A4 (en) 2022-12-28
SG11202112562XA (en) 2021-12-30
AU2020274165A1 (en) 2022-01-06
US20220242841A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2021013980A (es) Compuesto para el tratamiento de gota o hiperuricemia.
CR20220258A (es) Inhibidores de kras g12c
TN2017000374A1 (en) TGF-β INHIBITORS
JOP20190076B1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
MX2023010411A (es) Inhibidores de erbb/btk.
MX2022013051A (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
MX2021001952A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.
MX2023008954A (es) Inhibidores de los receptores erbb.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12020551589A1 (en) Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
SA521421973B1 (ar) عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي
MX2021006695A (es) Moduladores de trex1.
MX2021010321A (es) Compuestos macrociclicos.
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
EA202191545A1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
EA202092579A1 (ru) Оксозамещенное соединение
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
GEP20237459B (en) Thiadiazine derivatives
WO2020092127A8 (en) Novel sting agonists
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
NZ740037A (en) New effective aminoglycoside antibiotic for multidrug-resistant bacteria
PT1206444E (pt) Compostos que inibem a actividade da triptase
CR20220565A (es) Inhibidores de il4i1 y métodos de uso
WO2020185651A3 (en) Compositions and methods for treating huntington's disease